Journal Scans
Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
Role of CYP2D6 and ABCC2 Variants in Tamoxifen Failure
K Kiyotani, T Mushiroda, CK Imamura, N Hosono, T Tsunoda, M Kubo, Y Tanigawara, DA Flockhart, Z Desta, TC Skaar, F Aki, K Hirata, Y Takatsuka, M Okazaki, S Ohsumi, T Yamakawa, M Sasa, Y Nakamura, H Zembutsu
20100101
2010 Feb 1
J Clin Oncol
Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
J Clin Oncol. 2010 Feb 1; Epub ahead of print, K Kiyotani, T Mushiroda, CK Imamura, N Hosono, T Tsunoda, M Kubo, Y Tanigawara, DA Flockhart, Z Desta, TC Skaar, F Aki, K Hirata, Y Takatsuka, M Okazaki, S Ohsumi, T Yamakawa, M Sasa, Y Nakamura, H Zembutsu
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Up to 50% of patients with hormone-receptor−positive breast cancer who are treated with tamoxifen experience a relapse and subsequently die of their disease. This variability in response to tamoxifen is thought to be related to individual differences in the formation and elimination of 2 of the drug’s active metabolites, 4-hydroxytamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen). CYP2D6 is a key enzyme active in the production of these metabolites. Loss of CYP2D6, or decrease in its function...
